I'm with unifollower on this - Hastings looks an excellent...

I'm with unifollower on this - Hastings looks an excellent choice to manage the books, and now has a decent couple of backers to see Unilife through amgen and orbimed.

These things take time, and luckily for me I guess I'm a new SH and have the benefit of a low average SP to work with - I truly believe I'm lucky to have "found" unilife at this stage of its development.

In a dog eat dog market, I don't see a competitor offering what Unilife offers, and if the point of difference for the pharmas moving forward (with biosimilars etc becoming more common) then IMO we're in a very good place as long term investors.

Stay strong and prosper. I abide by the investing rules of Dr Spok.